Early diagnosis of sepsis-related hepatic dysfunction and its prognostic impact on survival: A prospective study with the LiMAx test

Critical Care

Volumn 17, Issue 5, 2013, Pages

  Kaffarnik, Magnus F ^a   Lock, Johan F ^a,b   Vetter, Hannah ^a   Ahmadi, Navid ^a   Lojewski, Christian ^a   Malinowski, Maciej ^a   Neuhaus, Peter ^a   Stockmann, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; EARLY DIAGNOSIS; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LIMAX TEST; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RESUSCITATION; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SURVIVAL; APACHE; ARTIFICIAL VENTILATION; DIAGNOSTIC USE; LIVER DISEASES; MIDDLE AGED; PROCEDURES; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

COLORING AGENT; INDOCYANINE GREEN;

ADULT; AGED; AGED, 80 AND OVER; APACHE; COLORING AGENTS; EARLY DIAGNOSIS; FEMALE; HUMANS; INDOCYANINE GREEN; LENGTH OF STAY; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RESPIRATION, ARTIFICIAL; RESUSCITATION; RISK FACTORS; SEPSIS;

EID: 84886736295     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13089     Document Type: Article

References (42)

1. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med 2000, 26:S64-S74. 10.1007/s001340051121, 10786961.
2. Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004, 32:1-12. 10.1097/01.CCM.0000105118.66983.19, 14707554.
3. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine 2003, 82:392-406. 10.1097/01.md.0000101573.54295.bd, 14663289.
4. Brienza N, Dalfino L, Cinnella G, Diele C, Bruno F, Fiore T. Jaundice in critical illness: promoting factors of a concealed reality. Intensive Care Med 2006, 32:267-274. 10.1007/s00134-005-0023-3, 16450099.
5. Harbrecht BG, Zenati MS, Doyle HR, McMichael J, Townsend RN, Clancy KD, Peitzman AB. Hepatic dysfunction increases length of stay and risk of death after injury. J Trauma 2002, 53:517-523. 10.1097/00005373-200209000-00020, 12352490.
6. Kramer L, Jordan B, Druml W, Bauer P, Metnitz PG. Incidence and prognosis of early hepatic dysfunction in critically ill patients - a prospective multicenter study. Crit Care Med 2007, 35:1099-1104. 10.1097/01.CCM.0000259462.97164.A0, 17334250.
7. Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Schoniger-Hekele M, Madl C, Schenk P. Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med 2011, 37:1302-1310. 10.1007/s00134-011-2248-7, 21647720.
8. Sakka SG. Assessing liver function. Curr Opin Crit Care 2007, 13:207-214. 10.1097/MCC.0b013e328012b268, 17327744.
9. Kimura S, Yoshioka T, Shibuya M, Sakano T, Tanaka R, Matsuyama S. Indocyanine green elimination rate detects hepatocellular dysfunction early in septic shock and correlates with survival. Crit Care Med 2001, 29:1159-1163. 10.1097/00003246-200106000-00014, 11395594.
10. Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 2002, 122:1715-1720. 10.1378/chest.122.5.1715, 12426276.
11. Kortgen A, Lindemann W, Bauer M. Monitoring of plasma disappearance rate of indocyanine green in a patient with necrotizing fasciitis and septic shock. Dtsch Med Wochenschr 2004, 129:2590-2593. 10.1055/s-2004-836080, 15558407.
12. Sakka S, Meier-Hellmann A. Indocyanine green for the assessment of liver function in critically ill patients. Yearbook of Intensive Care and Emergency Medicine 2001, 611-618. Berlin: Springer, Vincent JL.
13. Escorsell A, Mas A, Fernandez J, Garcia-Valdecasas JC. Limitations of use of the noninvasive clearance of indocyanine green as a prognostic indicator of graft function in liver transplantation. Transplant Proc 2012, 44:1539-1541. 10.1016/j.transproceed.2012.05.023, 22841207.
14. Hunton DB, Bollman JL, Hoffman HN. Studies of hepatic function with indocyanine green. Gastroenterology 1960, 39:713-724.
15. Stehr A, Ploner F, Traeger K, Theisen M, Zuelke C, Radermacher P, Matejovic M. Plasma disappearance of indocyanine green: a marker for excretory liver function?. Intensive Care Med 2005, 31:1719-1722. 10.1007/s00134-005-2826-7, 16231068.
16. Lock JF, Schwabauer E, Martus P, Videv N, Pratschke J, Malinowski M, Neuhaus P, Stockmann M. Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation. Liver Transpl 2010, 16:172-180. 10.1002/lt.21973, 20104485.
17. Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 2010, 12:139-146. 10.1111/j.1477-2574.2009.00151.x, 2826673, 20495659.
18. Stockmann M, Lock JF, Malinowski M, Seehofer D, Puhl G, Pratschke J, Neuhaus P. How to define initial poor graft function after liver transplantation? A new functional definition by the LiMAx test. Transpl Int 2010, 23:1023-1032. 10.1111/j.1432-2277.2010.01089.x, 20444241.
19. Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M, Lehmann S, Niehues SM, Schwabe M, Lemke AJ, Neuhaus P. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009, 250:119-125. 10.1097/SLA.0b013e3181ad85b5, 19561474.
20. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2001, 2003(31):1250-1256.
21. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup.
22. Wacharasint P, Nakada TA, Boyd JH, Russell JA, Walley KR. Normal-range blood lactate concentration in septic shock is prognostic and predictive. Shock (Augusta, Ga) 2012, 38:4-10.
23. Venkataraman R, Kellum JA. Defining acute renal failure: the RIFLE criteria. J Intensive Care Med 2007, 22:187-193. 10.1177/0885066607299510, 17712054.
24. Drews RE, Weinberger SE. Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med 2000, 162:347-351. 10.1164/ajrccm.162.2.ncc3-00, 10934051.
25. Mochida S, Takikawa Y, Nakayama N, Oketani M, Naiki T, Yamagishi Y, Ichida T, Tsubouchi H. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 2011, 41:805-812. 10.1111/j.1872-034X.2011.00860.x, 21884340.
26. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005, 41:1179-1197. 10.1002/hep.20703, 15841455.
27. Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. Systematic review: acute liver failure - one disease, more than 40 definitions. Aliment Pharmacol Ther 2012, 35:1245-1256. 10.1111/j.1365-2036.2012.05097.x, 22506515.
28. Recknagel P, Gonnert FA, Westermann M, Lambeck S, Lupp A, Rudiger A, Dyson A, Carre JE, Kortgen A, Krafft C, Popp J, Sponholz C, Fuhrmann V, Hilger I, Claus RA, Riedemann NC, Wetzker R, Singer M, Trauner M, Bauer M. Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med 2012, 9:e1001338. 10.1371/journal.pmed.1001338, 3496669, 23152722.
29. Inal MT, Memis D, Kargi M, Sut N. Prognostic value of indocyanine green elimination assessed with LiMON in septic patients. J Crit Care 2009, 24:329-334. 10.1016/j.jcrc.2008.11.012, 19327336.
30. Schneider L, Spiegel M, Latanowicz S, Weigand MA, Schmidt J, Werner J, Stremmel W, Eisenbach C. Noninvasive indocyanine green plasma disappearance rate predicts early complications, graft failure or death after liver transplantation. Hepatobiliary Pancreat Dis Int 2011, 10:362-368. 10.1016/S1499-3872(11)60061-1, 21813383.
31. Carcillo JA, Doughty L, Kofos D, Frye RF, Kaplan SS, Sasser H, Burckart GJ. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003, 29:980-984.
32. Sharpe DA, Mitchel IM, Kay EA, McGoldrick JP, Munsch CM, Kay PH. Enhancing liver blood flow after cardiopulmonary bypass: the effects of dopamine and dopexamine. Perfusion 1999, 14:29-36. 10.1177/026765919901400105, 10074644.
33. Heintz R, Svensson CK, Stoeckel K, Powers GJ, Lalka D. Indocyanine green: pharmacokinetics in the rabbit and relevant studies of its stability and purity. J Pharm Sci 1986, 75:398-402. 10.1002/jps.2600750417, 3723362.
34. Paumgartner G. The handling of indocyanine green by the liver. Schweiz Med Wochenschr 1975, 105:1-30.
35. Hunton DB, Bollman JL, Hoffman HN. The plasma removal on indocyanine green and sulfobromophthalein: effect of dosage and blocking agents. J Clin Invest 1961, 40:1648-1655. 10.1172/JCI104387, 290858, 13716909.
36. Baumgartner U, Scholmerich J, Feuerstein E, Baier P, Ihling C. Repetitive short-term bile duct obstruction and relief causes reproducible and reversible bile acid regurgitation. J Surg Res 2003, 110:222-227. 10.1016/S0022-4804(02)00082-3, 12697405.
37. Cotting J, Zysset T, Reichen J. Biliary obstruction dissipates bioelectric sinusoidal-canalicular barrier without altering taurocholate uptake. Am J Physiol 1989, 256:G312-G318.
38. Fuhrmann V, Jager B, Zubkova A, Drolz A. Hypoxic hepatitis - epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr 2010, 122:129-139. 10.1007/s00508-010-1357-6, 20361374.
39. Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, Schellongowski P, Angermayr B, Kitzberger R, Warszawska J, Holzinger U, Schenk P, Madl C. Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med 2009, 35:1397-1405. 10.1007/s00134-009-1508-2, 19506833.
40. Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones M. A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009, 35:717-721. 10.1007/s00134-008-1358-3, 19034423.
41. Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr Opin Gastroenterol 2007, 23:244-254. 10.1097/MOG.0b013e3280b17dfb, 17414839.
42. Sakka SG, van Hout N. Relation between indocyanine green (ICG) plasma disappearance rate and ICG blood clearance in critically ill patients. Intensive Care Med 2006, 32:766-769. 10.1007/s00134-006-0109-6, 16544120.